ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $48.27 million. The enterprise value is $49.40 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 16.25 million shares outstanding. The number of shares has increased by 82.50% in one year.
| Current Share Class | 16.25M |
| Shares Outstanding | 16.25M |
| Shares Change (YoY) | +82.50% |
| Shares Change (QoQ) | +16.16% |
| Owned by Insiders (%) | 16.62% |
| Owned by Institutions (%) | 2.16% |
| Float | 13.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 110.09 |
| Forward PS | n/a |
| PB Ratio | 8.27 |
| P/TBV Ratio | 6.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 126.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.42, with a Debt / Equity ratio of 0.17.
| Current Ratio | 0.42 |
| Quick Ratio | 0.07 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.27 |
Financial Efficiency
Return on equity (ROE) is -50.07% and return on invested capital (ROIC) is -22.41%.
| Return on Equity (ROE) | -50.07% |
| Return on Assets (ROA) | -15.70% |
| Return on Invested Capital (ROIC) | -22.41% |
| Return on Capital Employed (ROCE) | -39.95% |
| Revenue Per Employee | $20,592 |
| Profits Per Employee | -$218,691 |
| Employee Count | 19 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $23,982 in taxes.
| Income Tax | 23,982 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +332.44% in the last 52 weeks. The beta is 0.27, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | +332.44% |
| 50-Day Moving Average | 2.72 |
| 200-Day Moving Average | 1.24 |
| Relative Strength Index (RSI) | 50.94 |
| Average Volume (20 Days) | 235,662 |
Short Selling Information
The latest short interest is 617,978, so 3.80% of the outstanding shares have been sold short.
| Short Interest | 617,978 |
| Short Previous Month | 568,241 |
| Short % of Shares Out | 3.80% |
| Short % of Float | 4.58% |
| Short Ratio (days to cover) | 0.97 |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of $391,242 and -$4.16 million in losses. Loss per share was -$0.29.
| Revenue | 391,242 |
| Gross Profit | 390,946 |
| Operating Income | -3.88M |
| Pretax Income | -12.37M |
| Net Income | -4.16M |
| EBITDA | -3.85M |
| EBIT | -3.88M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $453,462 in cash and $1.59 million in debt, giving a net cash position of -$1.13 million or -$0.07 per share.
| Cash & Cash Equivalents | 453,462 |
| Total Debt | 1.59M |
| Net Cash | -1.13M |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | 9.49M |
| Book Value Per Share | 0.36 |
| Working Capital | -3.76M |
Full Balance SheetCash Flow
| Operating Cash Flow | -1.27M |
| Capital Expenditures | n/a |
| Free Cash Flow | -1.27M |
| FCF Per Share | -$0.08 |
Full Cash Flow StatementMargins
| Gross Margin | 99.92% |
| Operating Margin | -991.29% |
| Pretax Margin | -1,102.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |